注射型ドラッグデリバリー：市場影響と業界動向

Abstract

As competition in the pharmaceutical marketplace grows, companies are increasingly looking towards the drug delivery industry to maximize revenues and combat generic competitors. The search for more efficient drug delivery systems is also being driven by the rise in patient demand, healthcare and pharma cost containment, as much as by medical and technological advances.

The global market for drug delivery technology is worth in excess of US$25 billion in sales. Given its predicted annual growth of 15 percent, the market represents a considerable business opportunity, which has been reflected in the increasing number of drug delivery specialists. According to Arrowhead Publishers' new report entitled Injectable Drug Delivery: Market Impact and Industry Trends, injectables currently account for an estimated 15 percent of the global drug delivery market, with the US being the leading individual market.

Key features of this report:

• Overview of the drug delivery environment
• In-depth analysis of the injectable drug delivery industry, including main types and main marketed systems, and their advantages and disadvantages
• Comprehensive facts and figures for the injectable drug delivery market, including main players and key therapeutic areas
• Future trends in the injectables marketplace, shaped by medical and technological advances as much as demographic and epidemiological changes and industry needs
• Outlook for the injectable drug delivery technology

Who should buy this report?

• Stakeholders in the injectable drug delivery market
• Companies interested in understanding the impact and implications of securing the correct injectable drug delivery technology in terms of product placement, lifecycle management and competition in the marketplace
• Companies interested in understanding future opportunities in the injectable drug delivery sector provided by a combination of factors, including changing public health needs
• Pharma/biotech companies wishing to identify potential injectable drug delivery areas for partnerships and collaboration in order to examine a variety of profit maximization strategies

Table of Contents

1. Executive Summary

2. Introduction to Drug Delivery

• 2.1. Drug Delivery Technologies and Pharmaceutical Revenues
• 2.2. Drug Delivery Technologies and Wider Healthcare Market

3. Overview of Injectable Drug Delivery

• 3.1. Advantages and Disadvantages of Injectable Delivery
• 3.2. Types of Injectable Drug Delivery

4. Main Categories of Marketed Injectable Drug Delivery Systems

• 4.1. Sustained Release Injectable Systems
• 4.2. Advantages of Injectable Sustained-Release Formulations
• 4.3. Liposomal Systems
• 4.4. Advantages of Injectable Liposomal Formulations
• 4.5. Needleless Systems
• 4.6. Advantages of Injectable Needleless Formulations

5. Injectable Drug Delivery Market - Facts and Figures

• 5.1. Injectable Drug Delivery Market Overview
• 5.2. Key Therapeutic Areas for Injectable Drug Delivery
• 5.3. Acromegaly
• 5.4. Age-Related Macular Degeneration
• 5.5. Crohn' s Disease
• 5.6. Diabetes
• 5.7. Hepatitis C
• 5.8. Multiple Sclerosis
• 5.9. Neutropenia
• 5.10. Oncology
• 5.11. Pain
• 5.12. Psoriasis
• 5.13. Rheumatoid Arthritis

6. Drug Classes Appropriate for Injectable Drug Delivery

7. Main Players and Partnerships in the Injectable Drug Delivery Market

8. Key Company Involvement in the Field of Injectable Drug Delivery

• 8.1. Alkermes
• 8.2. ALZA
• 8.3. Aradigm
• 8.4. Bioject
• 8.5. Enzon
• 8.6. Ethypharm
• 8.7. MacroMed
• 8.8. Nektar Therapeutics
• 8.9. QLT
• 8.10. SkyePharma

9. Sales of Products Utilizing Injectable Drug Delivery Technology

10. Profiles of Key Products Using Injectable Drug Delivery Technology

• 10.1. Neulasta (Nektar/Amgen)
• 10.2. PEGASYS (Roche/Nektar)
• 10.3. PEG-Intron (Schering-Plough)
• 10.4. Risperdal Consta
• 10.5. Sandostatin (Novartis)
• 10.6. Vivitrol (Alkermes)

11. Recent Launches and Approvals in the Field of Injectable Drug Delivery

• 11.1. August 2006
• 11.2. July 2006
• 11.3. May 2006
• 11.4. April 2006
• 11.5. February 2006
• 11.6. January 2006

12. Current Research and Profiles of Key Pipeline Products in the Field of Injectable Drug Delivery

• 12.1. Cimzia (Nektar)
• 12.2. Mircera/CERA (Nektar)
• 12.3. Paliperidone Palmitate (Johnson & Johnson)
• 12.4. Intraject Sumatriptan (Zogenix)

13. Future of Injectable Drug Delivery Technology

• 13.1. Emerging Injectable Drug Delivery Technologies
• 13.2. Emerging Therapeutic Targets for Injectable Drug Delivery
• 13.3. Future Therapeutic Targets for Injectable Drug Delivery
• 13.4. New Technology and the Injectable Drug Delivery Market
• 13.5. New Threats to the Injectable Drug Delivery Market
• 13.6. New Healthcare Needs and the Injectable Drug Delivery

14. Outlook for Injectable Drug Delivery Technology